Clinical Trial Update: mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing mil60 to bevacizumab in treatment-naïve non-squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• mil60

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED